These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30216494)

  • 21. The management of moderate-to-severe chronic plaque psoriasis.
    Tonini A; Panduri S; D' Erme AM; Papadia F; Romanelli M; Krueger JG; Chiricozzi A
    G Ital Dermatol Venereol; 2017 Oct; 152(5):447-457. PubMed ID: 28534602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increase in antinuclear antibody levels through biologic treatment for psoriasis.
    Miki M; Endo C; Naka Y; Fukuya Y; Kobayashi S; Kawashima M; Tsunemi Y
    J Dermatol; 2019 Feb; 46(2):e50-e51. PubMed ID: 30051919
    [No Abstract]   [Full Text] [Related]  

  • 23. Reduced doses of biological therapies in psoriasis: a new potentially "sustainable" frontier of psoriasis treatment.
    Ribero S; Ortoncelli M; Mastorino L; Quaglino P; Dapavo P
    Expert Opin Biol Ther; 2023; 23(9):867-868. PubMed ID: 37553946
    [No Abstract]   [Full Text] [Related]  

  • 24. Switching of biologics in psoriasis: Reasons and results.
    Honda H; Umezawa Y; Kikuchi S; Yanaba K; Fukuchi O; Ito T; Nobeyama Y; Asahina A; Nakagawa H
    J Dermatol; 2017 Sep; 44(9):1015-1019. PubMed ID: 28488283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
    Al-Mutairi N; Nour T
    Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics.
    Levine D; Strober BE
    Semin Cutan Med Surg; 2010 Mar; 29(1):28-34. PubMed ID: 20430305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are biologics useful for nail psoriasis?
    Antúnez-Lay A; Cabrolier J; Andino-Navarrete R
    Medwave; 2016 Jan; 16 Suppl 1():e6363. PubMed ID: 26817583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polyphenotypic Psoriasis: A Report from the GRAPPA 2016 Annual Meeting.
    Kaskas N; Merola JF; Qureshi AA; Paek SY
    J Rheumatol; 2017 May; 44(5):695-696. PubMed ID: 28461530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
    Alwawi EA; Krulig E; Gordon KB
    Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced CCR9 expression levels in psoriatic skin are associated with poor clinical outcome to infliximab treatment.
    Koga A; Kajihara I; Yamada S; Makino K; Ichihara A; Aoi J; Makino T; Fukushima S; Jinnin M; Ihn H
    J Dermatol; 2016 May; 43(5):522-5. PubMed ID: 26507968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elderly psoriatic patients under biological therapies: an Italian experience.
    Ricceri F; Bardazzi F; Chiricozzi A; Dapavo P; Ferrara F; Mugheddu C; Romanelli M; Rongioletti F; Prignano F
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):143-146. PubMed ID: 29906311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current therapeutic approaches of psoriasis are affected by age at disease onset.
    Di Lernia V; Ficarelli E
    J Dermatolog Treat; 2014 Feb; 25(1):15-7. PubMed ID: 23210896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From conventional to cutting edge: the new era of biologics in treatment of psoriasis.
    Tzu J; Kerdel F
    Dermatol Ther; 2008; 21(2):131-41. PubMed ID: 18394087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psoriasis Trends and Practice Gaps.
    Gottlieb AB; Greb JE; Goldminz AM
    Dermatol Clin; 2016 Jul; 34(3):235-42. PubMed ID: 27363878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combining biologics with methotrexate in psoriasis: a systematic review.
    van Bezooijen JS; Prens EP; Pradeepti MS; Atiqi R; Schreurs MWJ; Koch BCP; van Gelder T; van Doorn MBA
    Br J Dermatol; 2015 Jun; 172(6):1676-1680. PubMed ID: 25470815
    [No Abstract]   [Full Text] [Related]  

  • 36. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New drugs and treatment targets in psoriasis.
    Kofoed K; Skov L; Zachariae C
    Acta Derm Venereol; 2015 Feb; 95(2):133-9. PubMed ID: 25111317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biologics for psoriasis: more drugs, new patient categories, but fresh challenges for clinical dermatologists.
    Pink AE; Smith CH
    Br J Dermatol; 2017 Jul; 177(1):7-8. PubMed ID: 28731243
    [No Abstract]   [Full Text] [Related]  

  • 39. Serum Fatty Acid-Binding Protein 4 is Increased in Patients with Psoriasis.
    Baran A; Świderska M; Bacharewicz-Szczerbicka J; Myśliwiec H; Flisiak I
    Lipids; 2017 Jan; 52(1):51-60. PubMed ID: 27864793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-tuberculous mycobacterial infections in psoriasis patients treated with biologics.
    Choi YM; Adelzadeh L; Wu JJ
    J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):e99-e101. PubMed ID: 26388307
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.